November 30, 2016 - By Adrian Mccoy · 0 Comments
Myriad Genetics Inc (NASDAQ:MYGN) institutional sentiment decreased to 0.97 in 2016 Q2. Its down -0.27, from 1.24 in 2016Q1. The ratio has dropped, as 123 institutional investors increased and opened new positions, while 99 sold and reduced stock positions in Myriad Genetics Inc. The institutional investors in our partner’s database now own: 77.80 million shares, down from 84.42 million shares in 2016Q1. Also, the number of institutional investors holding Myriad Genetics Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 22 Reduced: 77 Increased: 80 New Position: 43.
Myriad Genetics, Inc. is a molecular diagnostic company. The company has a market cap of $1.16 billion. The Firm is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It has a 12.76 P/E ratio. The Firm operates through two divisions: diagnostics and other.
About 157,210 shares traded hands. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 54.33% since April 27, 2016 and is downtrending. It has underperformed by 59.55% the S&P500.
Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on February, 7. They expect $0.23 EPS, down 48.89% or $0.22 from last year’s $0.45 per share. MYGN’s profit will be $15.96 million for 18.33 P/E if the $0.23 EPS becomes a reality. After $0.23 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.”
Sls Management Llc holds 7.34% of its portfolio in Myriad Genetics, Inc. for 109,300 shares. Tieton Capital Management Llc owns 101,790 shares or 3.03% of their US portfolio. Moreover, S&T Bank Pa has 1.68% invested in the company for 336,048 shares. The Maryland-based Campbell & Co Investment Adviser Llc has invested 1.53% in the stock. Taylor Frigon Capital Management Llc, a California-based fund reported 45,341 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 2 insider buys, and 1 insider sale for $380,926 net activity.
Ratings analysis reveals 24% of Myriad Genetics’s analysts are positive. Out of 17 Wall Street analysts rating Myriad Genetics, 4 give it “Buy”, 4 “Sell” rating, while 9 recommend “Hold”. The lowest target is $18 while the high is $52. The stock’s average target of $37 is 119.85% above today’s ($16.83) share price. MYGN was included in 30 notes of analysts from July 21, 2015. On Tuesday, September 15 the stock rating was maintained by Piper Jaffray with “Overweight”. Bank of America downgraded the stock to “Underperform” rating in Friday, July 29 report. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Market Perform” rating given on Wednesday, August 10 by Wells Fargo. The rating was maintained by Jefferies on Thursday, August 11 with “Hold”. Barclays Capital downgraded the shares of MYGN in a report on Wednesday, August 10 to “Equal-Weight” rating. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Buy” rating by Gabelli on Tuesday, July 21. The rating was maintained by UBS on Wednesday, August 10 with “Sell”. As per Wednesday, May 4, the company rating was maintained by Avondale. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Neutral” rating by PiperJaffray on Wednesday, August 10. The firm earned “Underweight” rating on Wednesday, August 10 by Morgan Stanley.
Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Firm is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Firm operates through two divisions: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing services and products to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology.
More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Fool.com which released: “Why Myriad Genetics, Inc. Got Knocked Down Today” on November 02, 2016, also Fool.com with their article: “Why Myriad Genetics, Inc. Got Crushed Today” published on October 10, 2016, Fool.com published: “Here’s Why Myriad Genetics, Inc. Had Its DNA Scrambled, Causing Its Stock to …” on September 07, 2016. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Fool.com and their article: “Why Myriad Genetics, Inc. Got Pummeled Today” published on August 10, 2016 as well as Fool.com‘s news article titled: “Bull Vs. Bear: Myriad Genetics, Inc.” with publication date: May 25, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy